Published in Antimicrob Agents Chemother on June 01, 2001
Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis (2013) 1.84
Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis (2005) 1.74
Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J Clin Microbiol (2002) 1.71
Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother (2002) 1.70
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother (2008) 1.66
Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ (2008) 1.60
Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother (2003) 1.57
Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis (2012) 1.55
Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J Clin Microbiol (2003) 1.53
High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. Antimicrob Agents Chemother (2003) 1.50
Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis (2007) 1.43
Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis (2003) 1.42
Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg Infect Dis (2004) 1.38
In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations. J Clin Microbiol (2002) 1.32
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother (2002) 1.30
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother (2003) 1.30
Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob (2008) 1.29
Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother (2014) 1.29
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain. Antimicrob Agents Chemother (2007) 1.28
Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis (2005) 1.26
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother (2007) 1.25
Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother (2003) 1.23
Macrolide efflux in Streptococcus pneumoniae is mediated by a dual efflux pump (mel and mef) and is erythromycin inducible. Antimicrob Agents Chemother (2005) 1.22
The multifaceted roles of antibiotics and antibiotic resistance in nature. Front Microbiol (2013) 1.21
New mutations and horizontal transfer of rpoB among rifampin-resistant Streptococcus pneumoniae from four Spanish hospitals. Antimicrob Agents Chemother (2005) 1.18
Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations. J Clin Microbiol (2004) 1.16
Aggregated antibiograms and monitoring of drug-resistant Streptococcus pneumoniae. Emerg Infect Dis (2003) 1.15
In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother (2004) 1.09
Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother (2004) 1.08
Laboratory-based surveillance of patients with bacterial meningitis in Egypt (1998-2004). Eur J Clin Microbiol Infect Dis (2007) 1.07
Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother (2006) 1.06
Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study. J Clin Microbiol (2004) 1.05
Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes. Antimicrob Agents Chemother (2007) 1.04
Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice. Infect Immun (2009) 1.04
Characterization of ermB gene transposition by Tn1545 and Tn917 in macrolide-resistant Streptococcus pneumoniae isolates. J Clin Microbiol (2005) 1.03
Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur J Clin Microbiol Infect Dis (2005) 1.01
Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland. Antimicrob Agents Chemother (2007) 1.00
Inhibition of T cells provides protection against early invasive pneumococcal disease. Infect Immun (2010) 1.00
Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America. J Clin Microbiol (2003) 1.00
Pathophysiology and treatment of bacterial meningitis. Ther Adv Neurol Disord (2009) 0.98
Novel antibacterial class. Antimicrob Agents Chemother (2003) 0.98
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother (2007) 0.97
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother (2003) 0.96
Total synthesis of (-)-4,8,10-tridesmethyl telithromycin. J Org Chem (2011) 0.95
Using hospital antibiogram data to assess regional pneumococcal resistance to antibiotics. Emerg Infect Dis (2003) 0.95
Expansion and evolution of the Streptococcus pneumoniae Spain9V-ST156 clonal complex in Poland. Antimicrob Agents Chemother (2010) 0.94
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother (2008) 0.93
Fractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 0.93
Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother (2002) 0.93
Trends in antimicrobial resistance in 1,968 invasive Streptococcus pneumoniae strains isolated in Spanish hospitals (2001 to 2003): decreasing penicillin resistance in children's isolates. J Clin Microbiol (2004) 0.91
Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary. Antimicrob Agents Chemother (2005) 0.89
Desmethyl Macrolides: Synthesis and Evaluation of 4,10-Didesmethyl Telithromycin. ACS Med Chem Lett (2012) 0.89
Factors influencing fluoroquinolone resistance. Emerg Infect Dis (2003) 0.88
Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis (2005) 0.88
Social-economic factors and irrational antibiotic use as reasons for antibiotic resistance of bacteria causing common childhood infections in primary healthcare. Eur J Pediatr (2011) 0.87
Phenotypic and molecular analysis of penicillin-nonsusceptible Streptococcus pneumoniae isolates in Poland. Antimicrob Agents Chemother (2006) 0.86
Increase of the M phenotype among erythromycin-resistant Streptococcus pneumoniae isolates from Spain related to the serotype 14 variant of the Spain9V-3 clone. Antimicrob Agents Chemother (2006) 0.86
Evaluating antibiograms to monitor drug resistance. Emerg Infect Dis (2005) 0.86
Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime. Antimicrob Agents Chemother (2003) 0.85
Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients. J Clin Microbiol (2005) 0.85
In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides. Antimicrob Agents Chemother (2003) 0.85
Deletion of arcD in Streptococcus pneumoniae D39 impairs its capsule and attenuates virulence. Infect Immun (2013) 0.84
Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials. Br J Clin Pharmacol (2008) 0.83
Desmethyl Macrolides: Synthesis and Evaluation of 4,8-Didesmethyl Telithromycin. ACS Med Chem Lett (2012) 0.83
Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother (2005) 0.81
Use of azithromycin in the treatment of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2008) 0.79
Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections. Antimicrob Agents Chemother (2003) 0.79
Antimicrobial Susceptibility Pattern of Invasive Pneumococcal Isolates in North West Nigeria. J Glob Infect Dis (2015) 0.78
Desmethyl Macrolides: Synthesis and Evaluation of 4,8,10-Tridesmethyl Cethromycin. ACS Med Chem Lett (2013) 0.78
Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics. Antimicrob Agents Chemother (2006) 0.78
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci. Antimicrob Agents Chemother (2006) 0.77
Involvement of aph(3')-IIa in the formation of mosaic aminoglycoside resistance genes in natural environments. Front Microbiol (2015) 0.76
Vancomycin and home health care. Emerg Infect Dis (2005) 0.75
The Ongoing Genetic Adaptation of Streptococcus pneumoniae. J Clin Microbiol (2016) 0.75
Genetic relatedness of Streptococcus pneumoniae isolates from paired blood and respiratory specimens. J Clin Microbiol (2007) 0.75
Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics. ACS Med Chem Lett (2014) 0.75
Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumonia. Curr Ther Res Clin Exp (2004) 0.75
Reasons for coming to hospital after treatment for community-acquired pneumonia on an ambulatory basis. Can Respir J (2006) 0.75
Telithromycin: a novel agent for the treatment of community-acquired upper respiratory infections. Proc (Bayl Univ Med Cent) (2004) 0.75
First Report of a Case of Pneumococcal Meningitis Which Did Not Respond to the Ceftriaxone Therapy despite the Isolated Organism Being Sensitive to This Antibiotic In Vitro. Case Rep Pulmonol (2011) 0.75
Delafloxacin: design, development and potential place in therapy. Drug Des Devel Ther (2017) 0.75
Resistance, serotype and genetic diversity of Streptococcus pneumoniae-resistant strains isolated in the West Pomerania region of Poland in the years 2001-2005. Eur J Clin Microbiol Infect Dis (2008) 0.75
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med (1999) 10.06
Pneumococcal resistance to antibiotics. Clin Microbiol Rev (1990) 9.76
Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother (1996) 8.65
Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med (2000) 8.05
Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother (1999) 7.94
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother (1996) 5.68
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med (1995) 4.38
Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother (1990) 4.14
Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J Infect Dis (1991) 4.00
Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn Microbiol Infect Dis (1996) 3.29
Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.19
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother (2000) 3.00
Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics. Antimicrob Agents Chemother (1996) 2.72
Relapsing pneumococcal meningitis: isolation of an organism with decreased susceptibility to penicillin G. J Pediatr (1974) 2.68
Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98. Emerg Infect Dis (2000) 2.63
Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist (1998) 2.62
Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis (1999) 2.16
Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev (1998) 2.13
Alterations in PBP 1A essential-for high-level penicillin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 1.98
Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States. Clin Infect Dis (1998) 1.96
The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis (2000) 1.69
Use of clindamycin disks To detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children. J Clin Microbiol (2000) 1.29
Use of penicillin MICs to predict in vitro activity of other beta-lactam antimicrobial agents against Streptococcus pneumoniae. J Clin Microbiol (2001) 0.99
Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol (2002) 3.30
Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother (1997) 2.91
Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98. Emerg Infect Dis (2000) 2.63
Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother (1996) 2.22
Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis (1999) 2.16
The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis (2004) 2.08
Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States. Clin Infect Dis (1998) 1.96
The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis (2001) 1.91
Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1. J Exp Med (1995) 1.81
Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis (1997) 1.73
In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother (2000) 1.64
Multicenter laboratory evaluation of the bioMérieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol (1997) 1.64
Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. Am J Obstet Gynecol (2000) 1.53
Comparison of identification systems for Staphylococcus epidermidis and other coagulase-negative Staphylococcus species. Diagn Microbiol Infect Dis (1994) 1.49
Simultaneous respiratory tract colonization by multiple strains of nontypeable haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis (1999) 1.49
Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis (2007) 1.43
A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions. Int J Antimicrob Agents (1999) 1.43
Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother (1996) 1.39
Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: a report from the College of American Pathologists Microbiology Proficiency Survey Program. Arch Pathol Lab Med (1999) 1.30
Four-day incubation period for blood culture bottles processed with the Difco ESP blood culture system. J Clin Microbiol (1997) 1.27
The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother (2003) 1.23
Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-99. Diagn Microbiol Infect Dis (2001) 1.18
Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae. Emerg Infect Dis (2000) 1.17
The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis (1998) 1.07
In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii. J Chemother (2005) 1.04
Outbreak of severe Pseudomonas aeruginosa infections caused by a contaminated drain in a whirlpool bathtub. Clin Infect Dis (2000) 1.03
Assessment of the oxacillin disk screening test for determining penicillin resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis (1997) 0.94
Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci. J Clin Microbiol (1998) 0.93
Comparative evaluation of etest for susceptibility testing Neisseria meningitidis with eight antimicrobial agents. An investigation using U.S. Food and Drug Administration regulatory criteria. Diagn Microbiol Infect Dis (1997) 0.92
Vancomycin-resistant Enterococcus raffinosus: molecular epidemiology, species identification error, and frequency of occurrence in a national resistance surveillance program. Diagn Microbiol Infect Dis (1997) 0.90
Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998. Antimicrob Agents Chemother (2000) 0.88
Comparison of results generated by serotyping, pulsed-field restriction analysis, ribotyping, and repetitive-sequence PCR used to characterize penicillin-resistant pneumococci from the United States. J Clin Microbiol (2001) 0.87
Pneumococci can persistently colonize adult patients with chronic respiratory disease. J Clin Microbiol (2012) 0.86
Antibiotic susceptibility and molecular epidemiology of nasopharyngeal pneumococci from Spanish children. Clin Microbiol Infect (2008) 0.84
Molecular epidemiology of paediatric invasive pneumococcal disease in southern Spain after the introduction of heptavalent pneumococcal conjugate vaccine. Clin Microbiol Infect (2007) 0.83
In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diagn Microbiol Infect Dis (1996) 0.83
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections. J Chemother (2010) 0.80
Collaborative evaluation of an erythromycin-clindamycin combination well for detection of inducible clindamycin resistance in beta-hemolytic streptococci by use of the CLSI broth microdilution method. J Clin Microbiol (2011) 0.80
Evolution and genetic diversity of the Spain23F-ST81 clone causing adult invasive pneumococcal disease in Barcelona (1990-2012). J Antimicrob Chemother (2013) 0.79
Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centers. Antimicrob Agents Chemother (1999) 0.78
Macrolide use identified as risk factor for macrolide-resistant Streptococcus pneumoniae in a 17-center case-control study. Eur J Clin Microbiol Infect Dis (2006) 0.76
Ultrastructural localization of factor VIII-related antigen in cultured human brain microvessel endothelial cells. J Histochem Cytochem (1992) 0.76
Correction: Castanea sativa (European Chestnut) Leaf Extracts Rich in Ursene and Oleanene Derivatives Block Staphylococcus aureus Virulence and Pathogenesis without Detectable Resistance. PLoS One (2016) 0.75
Resistance among Streptococcus pneumoniae: patterns, mechanisms, interpreting the breakpoints. Am J Manag Care (2000) 0.75
Exploration of beta-turn scaffolding motifs as components of sialyl Le(X) mimetics and their relevance to P-selectin. Bioorg Med Chem Lett (1998) 0.75
Promiscuous Watson-Crick cross-pairing within the family of pentopyranosyl (4'-->2') oligonucleotides. Org Lett (1999) 0.75
Roundtable discussion. Optimizing the use of antimicrobial therapy. Am J Manag Care (2000) 0.75
Empathic understanding: an important skill for those who work with older adults. Long Term Care Health Serv Adm Q (1980) 0.75
Partial liquid ventilation with perfluorocarbon in the treatment of rats with lethal pneumococcal pneumonia. Anesthesiology (1998) 0.75